Stock Price Quote

SUN PHARMA ADVANCED RESEARCH COMPANY LTD.

NSE : SPARCBSE : 532872ISIN CODE : INE232I01014Industry : Business SupportHouse : Sun Pharma
BSE224.15-2.2 (-0.97 %)
PREV CLOSE ( ) 226.35
OPEN PRICE ( ) 225.50
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 33718
TODAY'S LOW / HIGH ( )223.15 227.50
52 WK LOW / HIGH ( )196.45 474
NSE224.57-1.49 (-0.66 %)
PREV CLOSE( ) 226.06
OPEN PRICE ( ) 227.30
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 299462
TODAY'S LOW / HIGH( ) 223.40 227.65
52 WK LOW / HIGH ( )196.1 472.8
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 31-03 2006
Management Info
Dilip S Shanghvi - Chairman - Managing Director
Registered Office

Address Plot No.5 & 6/1, Savli G. I. D. C. Estate,Savli - Vadodara Highway,Manjusar ,
Vadodara,
Gujarat-391775

Phone 0265- 2330815

Email secretarial@sparcmail.com

Website www.sparc.life

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

05Aug Sun Pharma Advanced Research Company i
Pursuant to Regulation 30 of the Securities and Exchange Board of India..
10Apr Sun Pharma Advanced Research Company i
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosur..
10Apr Sun Pharma Advanced Research Company i
Sun Pharma Advanced Research Company has confirmed that activities in re..
07Mar Sun Pharma Advanced Research Company i
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclo..
04Jan Sun Pharma Advanced Research Company i
Sun Pharma Advanced Research Company has confirmed that the Company is i..

Financials

in Millions
QTR Jun 24 ANNUAL 24
Net Profit-968.4-3881.1
Gross Profit -968.4 -3881.1
Operating Profit -935.6-3743.2
Net Sales 168.1755.5

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Medi Assist Health (BSE)
peergroup  692.70 (5.58%)
M.Cap ( in Cr)4867.75
Dynavision (BSE)
peergroup  378.90 (5.75%)
M.Cap ( in Cr)145.54
Syngene Internation. (BSE)
peergroup  938.25 (1.51%)
M.Cap ( in Cr)37784.13
AGS Transact Tech (BSE)
peergroup  117.60 (5.90%)
M.Cap ( in Cr)1425.93
RK Swamy (BSE)
peergroup  253.90 (2.34%)
M.Cap ( in Cr)1283.38

Shareholding Pattern

PROMOTERS 65.67%
NON-INSTITUTION 31.52%
MUTUAL FUNDS/UTI 0.08%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Sun Pharma Advanced Research Company Ltd.

Sun Pharma Advanced Research Company Ltd. was incorporated in the year 2006. Its today's share price is 224.15. Its current market capitalisation stands at Rs 7274.15 Cr. In the latest quarter, company has reported Gross Sales of Rs. 755.45 Cr and Total Income of Rs.1050.15 Cr. The company's management includes Vidhi Dilip Shanghvi, T Rajamannar, Sudhir V Valia, Robert J Spiegel, Ferzaan Engineer, Bhavna Doshi, Dilip S Shanghvi, Kajal Damania.

It is listed on the BSE with a BSE Code of 532872 , NSE with an NSE Symbol of SPARC and ISIN of INE232I01014. It's Registered office is at Plot No.5 & 6/1, Savli G. I. D. C. Estate,Savli - Vadodara Highway,Manjusar Vadodara-391775, Gujarat. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells, Deloitte Haskins & Sells LLP, Deloittee Haskins & Sells, SRBC & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.